The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet’s Disease
- 27 August 2018
- journal article
- research article
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 28 (2) , 298-304
Abstract
Purpose: To identify factors associated with sustained response to interleukin (IL)-1 inhibition among demographic, clinical and therapeutic data in patients with Behçet disease (BD). Methods: BD patients treated with anakinra or canakinumab were enrolled. Patients were divided into two groups according to the clinical response: group 1 included subjects showing a treatment duration of at least 52 weeks and no secondary inefficacy during the first follow-up year; the remaining patients were included in the group 2. Demographic, clinical and therapeutic data were analyzed to identify significant differences between groups. Results: Eighteen patients were included in group 1 and 18 patients in group 2. A better response to IL-1 inhibitors was significantly more common among patients with BD-related uveitis (p = 0.006) and patients with a longer disease duration (p = 0.03). Conclusion: IL-1 blockade is effective in BD, especially in the subset of patients presenting eye involvement and in those with long-lasting disease.Keywords
This publication has 31 references indexed in Scilit:
- Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory DisordersMediators of Inflammation, 2013
- Efficacy of Infliximab in Intestinal Behçet’s DiseaseInflammatory Bowel Diseases, 2013
- Behçet's SyndromeRheumatic Disease Clinics of North America, 2013
- Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye diseaseAnnals of the Rheumatic Diseases, 2012
- Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot studyAnnals of the Rheumatic Diseases, 2012
- Resistant Behçet Disease Responsive to AnakinraAnnals of Internal Medicine, 2008
- Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to Brazilian Portuguese languageClinical Rheumatology, 2006
- Hydrocephalus in CINCA syndrome treated with anakinraChild's Nervous System, 2006
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome.Annals of the Rheumatic Diseases, 1984